Immunotherapy has revolutionized cancer treatment, with ICIs including monoclonal anti‐PD‐1, anti‐PD‐L1, and anti‐CTLA‐4 having significantly improved survival outcomes in lung cancer and melanoma patients.16, 17, 18. This evidence concerns the gene CTLA4 and lung cancer.